Good News! Another Stem Cell Clinical Research Project Has Been Approved by the National Health Commission

Release time:

2025-03-01

Regenerative medicine technologies, epitomized by stem cell technology, represent the “third medical revolution” following pharmacological and surgical therapies. Stem cells possess the remarkable ability to differentiate into and form any type of tissue in vivo, while also self-replicating to generate additional stem cells, making them a key frontier area of international medical research in recent years.

Good News! Another Stem Cell Clinical Research Project Has Been Approved by the National Health Commission

On October 20, 2021, the project “A Prospective, Randomized, Controlled Clinical Study on the Use of Human Umbilical Cord Mesenchymal Stem Cell Injection for the Treatment of Diabetic Foot Ulcers,” submitted by President Jin Peisheng and his team at the Affiliated Hospital of Xuzhou Medical University, successfully passed the filing and approval process with the National Health Commission. This marks the first stem-cell–based research project for the treatment of diabetic foot to be approved nationwide. All preparatory work is now in place, and the study plans to recruit 60 patients with diabetic foot to receive free umbilical cord mesenchymal stem cell therapy.

Each of us begins as a fertilized egg about 0.5 millimeters in size and gradually develops into a complex human body composed of roughly 60 trillion cells of more than 200 different types. On average, about 150 million red blood cells die every day, and 30,000 skin cells shed each minute; in adults, the skeletal system is completely renewed every 7 to 10 years. All of these processes rely on stem cells differentiating into new cells to replenish the lost or damaged ones. In essence, Our growth and development, as well as our metabolism, can only proceed normally thanks to the presence of stem cells.

Related News

Overview of Bioanalytical Methods for Cell Therapy Products

Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.

2026-04-03

Bioanalytical Strategies for CGT Products: Selected Developments and Validation of qPCR/ddPCR Methodologies

With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.

2026-04-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road

Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.

2025-03-01

Share